Farmaceutica Remedia SABVB: RMAH

Farmaceutica Remedia: Closed period 19.10.2026-18.11.2026 (RMAH 20261016151506 RMAH RC 2026 Q3 results closed period EN)

· Issued by Farmaceutica Remedia SA

Summary by 6ix AI

Farmaceutica REMEDIA SA will publish its financial results for the third quarter of 2026 on November 18, 2026, at 18:30, after market close. From October 19, 2026 to November 18, 2026, its managers and insiders may not trade the company's securities.

Key details

  • The ban covers people with management responsibilities and those considered to have access to privileged (non-public) information, trading directly or indirectly, for themselves or for others.
  • It applies to the company's shares, bonds, debt securities and other derivative financial instruments.
  • These persons may resume trading on November 19, 2026.
  • Farmaceutica REMEDIA SA is listed on the Bucharest Stock Exchange, Standard Category.

6ix AI wrote this summary from the release below and checked it against the release.

On 6ix: 6ix.com/news/farmaceutica-remedia-s-a-closed-period-19102026-18112026-rmah-20261016151506-rmah-rc-2026-q3-results-closed-period-en

CURRENT REPORT according to Law no. 24/2017 regarding issuers of financial instruments and market operations and ASF Regulation no. 5/2018 on issuers of financial instruments and market operations

Report date:

16.10.2026

Name of issuer:

Farmaceutica REMEDIA S.A.

Registered office:

Deva, no. 2, Nicolae Bălcescu Blvd

Tel/ fax no:

+40 254 22 32 60 / +40 254 22 61 97

ORC no:

2115198

Trade Registry no:

J1991000700203

Subscribed and paid-in capital:

LEI 9.548.082

Regulated market:

Bucharest Stock Exchange, Standard Category

Important events to report:

Dear investors,

Farmaceutica REMEDIA SA (the issuer) informs investors that on 18.11.2026, at 18:30, the Company will publish the financial results for the 3rd Quarter of 2026.

Therefore, during the following period: from October 19, 2026 to November 18, 2026, the persons who, according to the provisions of ASF Regulation no. 5/2018, Law no. 24/2017 and EU Regulations no. 522/2016 and no. 596/2014, exercise management responsibilities within Farmaceutica REMEDIA SA, as well as those who are considered to have access to privileged information ("insider"), are not entitled to carry out any transaction in their own name or on behalf of a third party, directly or indirectly, related to shares, bonds, debt securities or other derivative financial instruments of Farmaceutica REMEDIA SA.

These persons will be able to resume trading on 19.11.2026, after Farmaceutica REMEDIA SA will publish its Q3 2026 financial results on 18.11.2026, at 18:30, after market close.

Chairman of the Board of Administrators,

"TARUS" - Valentin Norbert TARUS e.U.

Farmaceutica Remedia SA on 6ix

Story so far

Earlier from Farmaceutica Remedia

All Farmaceutica Remedia news releases